$ASMB
Assembly Biosciences Inc

2024 Q4 Form 10-Q Financial Statement

#000095017024123402 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $6.845M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.220M
YoY Change -19.94%
% of Gross Profit
Research & Development $13.52M $10.82M
YoY Change 24.86% -40.3%
% of Gross Profit
Depreciation & Amortization $120.0K
YoY Change -10.45%
% of Gross Profit
Operating Expenses $17.80M $15.05M
YoY Change 18.29% -35.7%
Operating Profit -$10.96M -$15.05M
YoY Change -27.19% -35.7%
Interest Expense $630.0K
YoY Change 146.09%
% of Operating Profit
Other Income/Expense, Net $1.343M $628.0K
YoY Change 113.85% 145.31%
Pretax Income -$9.613M -$14.42M
YoY Change -33.34% -37.7%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$9.613M -$14.42M
YoY Change -33.34% -37.7%
Net Earnings / Revenue -140.44%
Basic Earnings Per Share -$1.51 -$0.27
Diluted Earnings Per Share -$1.51 -$0.27
COMMON SHARES
Basic Shares Outstanding 6.356M 6.346M 52.61M
Diluted Shares Outstanding 6.351M 52.57M

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $94.95M $46.21M
YoY Change 105.48% -57.47%
Cash & Equivalents $28.45M $26.66M
Short-Term Investments $66.50M $19.55M
Other Short-Term Assets $3.500M
YoY Change -32.45%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00
Total Short-Term Assets $98.21M $49.67M
YoY Change 97.72% -56.84%
LONG-TERM ASSETS
Property, Plant & Equipment $316.0K $561.0K
YoY Change -43.67% -35.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $312.0K $552.0K
YoY Change -43.48% -65.78%
Total Long-Term Assets $2.049M $1.957M
YoY Change 4.7% -69.6%
TOTAL ASSETS
Total Short-Term Assets $98.21M $49.67M
Total Long-Term Assets $2.049M $1.957M
Total Assets $100.3M $51.63M
YoY Change 94.2% -57.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.335M $758.0K
YoY Change 76.12% -60.97%
Accrued Expenses $4.765M $3.886M
YoY Change 22.62% -31.66%
Deferred Revenue $32.62M
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $41.64M $7.132M
YoY Change 483.78% -53.87%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $2.800M
YoY Change -23.31%
Total Long-Term Liabilities $2.800M
YoY Change -23.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $41.64M $7.132M
Total Long-Term Liabilities $2.800M
Total Liabilities $74.26M $9.915M
YoY Change 648.96% -48.12%
SHAREHOLDERS EQUITY
Retained Earnings -$815.6M -$774.8M
YoY Change 5.27% 10.35%
Common Stock $841.7M $816.8M
YoY Change 3.06% 1.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.00M $41.71M
YoY Change
Total Liabilities & Shareholders Equity $100.3M $51.63M
YoY Change 94.2% -57.51%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$9.613M -$14.42M
YoY Change -33.34% -37.7%
Depreciation, Depletion And Amortization $120.0K
YoY Change -10.45%
Cash From Operating Activities -$13.84M
YoY Change -30.18%
INVESTING ACTIVITIES
Capital Expenditures $130.0K
YoY Change -227.45%
Acquisitions
YoY Change
Other Investing Activities $19.02M
YoY Change -39.68%
Cash From Investing Activities $18.88M
YoY Change -39.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -13.84M
Cash From Investing Activities 18.88M
Cash From Financing Activities 0.000
Net Change In Cash 5.040M
YoY Change -56.59%
FREE CASH FLOW
Cash From Operating Activities -$13.84M
Capital Expenditures $130.0K
Free Cash Flow -$13.97M
YoY Change -29.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001426800
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0833
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0833
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0833
CY2024Q3 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#CashEquivalentsMember
CY2024Q3 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#CashEquivalentsMember
CY2024Q3 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#CashEquivalentsMember
CY2024Q3 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#CashEquivalentsMember
CY2023Q4 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#CashEquivalentsMember
CY2023Q4 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#CashEquivalentsMember
CY2023Q4 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#CashEquivalentsMember
CY2023Q4 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#CashEquivalentsMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35005
dei Entity Registrant Name
EntityRegistrantName
ASSEMBLY BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8729264
dei Entity Address Address Line1
EntityAddressAddressLine1
Two Tower Place
dei Entity Address Address Line2
EntityAddressAddressLine2
7th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
833
dei Local Phone Number
LocalPhoneNumber
509-4583
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
ASMB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6356286
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28452000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19841000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
66502000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
110406000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
43000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3259000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3497000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
98213000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
133787000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
316000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
385000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1421000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2339000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
312000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
312000
CY2024Q3 us-gaap Assets
Assets
100262000
CY2023Q4 us-gaap Assets
Assets
136823000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1335000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
461000
CY2024Q3 asmb Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1586000
CY2023Q4 asmb Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
885000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4765000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5744000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
32620000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
30915000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1329000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1220000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
41635000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
39225000
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
32511000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
55379000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
113000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1122000
CY2024Q3 us-gaap Liabilities
Liabilities
74259000
CY2023Q4 us-gaap Liabilities
Liabilities
95726000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6354414
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6354414
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5482752
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5482752
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
6000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
841743000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
826921000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-156000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-81000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-815590000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-785748000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
26003000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
41097000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
100262000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
136823000
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6845000
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
21163000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13515000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10824000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41653000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37894000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4286000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4224000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13398000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14201000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
17801000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
15048000
us-gaap Operating Expenses
OperatingExpenses
55051000
us-gaap Operating Expenses
OperatingExpenses
52095000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10956000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15048000
us-gaap Operating Income Loss
OperatingIncomeLoss
-33888000
us-gaap Operating Income Loss
OperatingIncomeLoss
-52095000
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
1343000
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
628000
us-gaap Interest Income Other
InterestIncomeOther
4452000
us-gaap Interest Income Other
InterestIncomeOther
1829000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1343000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
628000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4452000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1829000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9613000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14420000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29436000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-50266000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
406000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-9613000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14420000
us-gaap Net Income Loss
NetIncomeLoss
-29842000
us-gaap Net Income Loss
NetIncomeLoss
-50266000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
137000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
50000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-75000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
528000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9476000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14370000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29917000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49738000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.29
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.61
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6351431
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6351431
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4380444
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4380444
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5827750
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5827750
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4329260
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4329260
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
34682000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
137000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
797000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-9613000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
26003000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
54949000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
50000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1135000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14420000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
41714000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
41097000
asmb Issuance Of Common Stock And Warrants In Registered Direct Offering And Private Placement Net Of Issuance Costs Value
IssuanceOfCommonStockAndWarrantsInRegisteredDirectOfferingAndPrivatePlacementNetOfIssuanceCostsValue
12395000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
55000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-75000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2369000
us-gaap Net Income Loss
NetIncomeLoss
-29842000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
26003000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
82664000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4546000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
80000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
528000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4162000
us-gaap Net Income Loss
NetIncomeLoss
-50266000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
41714000
us-gaap Profit Loss
ProfitLoss
-29842000
us-gaap Profit Loss
ProfitLoss
-50266000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
97000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
366000
us-gaap Share Based Compensation
ShareBasedCompensation
2369000
us-gaap Share Based Compensation
ShareBasedCompensation
4160000
asmb Accretion Amortization Of Investments In Marketable Debt Securities
AccretionAmortizationOfInvestmentsInMarketableDebtSecurities
3065000
asmb Accretion Amortization Of Investments In Marketable Debt Securities
AccretionAmortizationOfInvestmentsInMarketableDebtSecurities
534000
asmb Noncash Rent Expense
NoncashRentExpense
1064000
asmb Noncash Rent Expense
NoncashRentExpense
2525000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-43000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-944000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-238000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-951000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-337000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
874000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1735000
asmb Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
701000
asmb Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
-1503000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-979000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-3429000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-21163000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
asmb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1047000
asmb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2720000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50710000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50904000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
96500000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
46315000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
49605000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
25615000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
184000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
46867000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
20516000
asmb Proceeds From Issuance Of Common Stock And Warrants In Registered Direct Offering And Private Placement Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsInRegisteredDirectOfferingAndPrivatePlacementNetOfIssuanceCosts
12395000
asmb Proceeds From Issuance Of Common Stock And Warrants In Registered Direct Offering And Private Placement Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsInRegisteredDirectOfferingAndPrivatePlacementNetOfIssuanceCosts
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4546000
asmb Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
55000
asmb Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
80000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12454000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4626000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8611000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25762000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19841000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
52418000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28452000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26656000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
asmb Number Of Approved Products
NumberOfApprovedProducts
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant estimates inherent in the preparation of the accompanying unaudited condensed consolidated financial statements include estimates for revenue recognition and costs incurred but not yet invoiced for research and development accruals.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible these external factors could have an effect on the Company’s estimates and could cause actual results to differ materially from those estimates and assumptions.</span></p>
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
In January 2024, the Company's stockholders approved a reverse stock split of its common stock at a range of ratios between 1-for-7 to 1-for-17, and the Company's board of directors approved the implementation of the reverse stock split at a ratio of 1-for-12 (the Reverse Stock Split). The Reverse Stock Split was effective as of February 9, 2024 and the Company regained compliance with the minimum bid price requirement in February 2024.
CY2024Q1 asmb Stock Outstanding During Period Shares Reverse Stock Splits
StockOutstandingDuringPeriodSharesReverseStockSplits
65800000
CY2024Q1 asmb Stock Outstanding During Period Shares Reverse Stock Splits
StockOutstandingDuringPeriodSharesReverseStockSplits
5500000
CY2024Q1 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
0
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-9613000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14420000
us-gaap Net Income Loss
NetIncomeLoss
-29842000
us-gaap Net Income Loss
NetIncomeLoss
-50266000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6351431
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6351431
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4380444
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4380444
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5827750
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5827750
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4329260
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4329260
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.29
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.61
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1827998
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
926240
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
27840000
CY2024Q3 asmb Cash And Cash Equivalent Gross Unrealized Gain
CashAndCashEquivalentGrossUnrealizedGain
0
CY2024Q3 asmb Cash And Cash Equivalent Gross Unrealized Loss
CashAndCashEquivalentGrossUnrealizedLoss
0
CY2024Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
27840000
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
66385000
CY2024Q3 asmb Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
117000
CY2024Q3 asmb Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
0
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
66502000
CY2024Q3 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost
94225000
CY2024Q3 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain
117000
CY2024Q3 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss
0
CY2024Q3 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue
94342000
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
18982000
CY2023Q4 asmb Cash And Cash Equivalent Gross Unrealized Gain
CashAndCashEquivalentGrossUnrealizedGain
0
CY2023Q4 asmb Cash And Cash Equivalent Gross Unrealized Loss
CashAndCashEquivalentGrossUnrealizedLoss
0
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
18982000
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
110214000
CY2023Q4 asmb Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
195000
CY2023Q4 asmb Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
3000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
110406000
CY2023Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost
129196000
CY2023Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain
195000
CY2023Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss
3000
CY2023Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue
129388000
CY2023Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2024Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
0
CY2024Q3 asmb Accured Interest Receivable
AccuredInterestReceivable
400000
CY2023Q4 asmb Accured Interest Receivable
AccuredInterestReceivable
300000
CY2024Q3 asmb Fair Value Assets Between Levels Transfers Amount
FairValueAssetsBetweenLevelsTransfersAmount
0
CY2023Q4 asmb Fair Value Assets Between Levels Transfers Amount
FairValueAssetsBetweenLevelsTransfersAmount
0
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4124000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5484000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
641000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
260000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4765000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5744000
CY2024Q3 asmb Warrants Exercised During Period Shares
WarrantsExercisedDuringPeriodShares
0
asmb Warrants Exercised During Period Shares
WarrantsExercisedDuringPeriodShares
0
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
797000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1135000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2369000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4160000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
2900000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M6D
CY2024Q3 asmb Share Based Compensation Arrangement Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementFairValueAssumptionsExercisePrice
13.24
CY2023Q3 asmb Share Based Compensation Arrangement Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementFairValueAssumptionsExercisePrice
11.76
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
86294000
asmb Contract With Customer Liability In Additions
ContractWithCustomerLiabilityInAdditions
0
asmb Contract With Customer Liability In Deduction
ContractWithCustomerLiabilityInDeduction
21163000
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
65131000
CY2024Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
6845000
CY2023Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
21163000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0
CY2024Q3 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2023Q3 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2024Q3 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
800000
CY2023Q3 asmb Milestone Payment Diligence Maintenance Fees
MilestonePaymentDiligenceMaintenanceFees
0
CY2024Q3 asmb Milestone Payment Diligence Maintenance Fees
MilestonePaymentDiligenceMaintenanceFees
0
asmb Milestone Payment Diligence Maintenance Fees
MilestonePaymentDiligenceMaintenanceFees
100000
asmb Milestone Payment Diligence Maintenance Fees
MilestonePaymentDiligenceMaintenanceFees
100000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-123402-index-headers.html Edgar Link pending
0000950170-24-123402-index.html Edgar Link pending
0000950170-24-123402.txt Edgar Link pending
0000950170-24-123402-xbrl.zip Edgar Link pending
asmb-20240930.htm Edgar Link pending
asmb-20240930.xsd Edgar Link pending
asmb-ex31_1.htm Edgar Link pending
asmb-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
asmb-20240930_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending